Rafael Henrique | SOPA Images | AP The stock of Hims & Hers fell Friday after a legal threat from Novo Nordisk. The online teleheath company announced on Thursday plans to launch a cheaper, copycat version of Novo’s weight loss pill, prompting Novo to take legal action. Hims stock spiked as much as 15% on…
President Donald Trump makes an announcement from the Oval Office at the White House in Washington, Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday announced the launch of TrumpRx — a direct-to-consumer website that is key to his administration’s efforts to lower prescription drug costs in the U.S. The president said…
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. Tom Little | Reuters Novo Nordisk said Thursday it will take legal action against Hims & Hers after the telehealth provider announced it would launch a cheaper copycat version of Novo’s Wegovy weight loss…
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The pharmaceutical giant…
Novo Nordisk‘s U.S. shares plummeted late Tuesday after the company said it sees sales and profit growth declining this year, expecting a sales hit. The company published the forecast as it reported full-year 2025 sales, ahead of the quarterly report expected Wednesday morning. Novo’s American depositary shares fell 11% as of 12:05 pm ET. The…
Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major catalyst for the rollout of the company’s closely watched experimental weight loss pill, orforglipron. In an exclusive interview with CNBC, Ricks said Lilly expects to have Medicare coverage for the treatment “immediately following that launch, and that…
Eli Lilly Chair and CEO Dave Ricks speaks during a press conference in Houston, Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Friday said it will spend more than $3.5 billion to build a manufacturing plant in Pennsylvania’s Lehigh Valley that will help make its next-generation obesity drugs. That includes a closely watched…
Drugmakers Roche and Sanofi’s latest earnings were largely as expected, with the companies talking up the potential of experimental medicines ahead of a looming “patent cliff” for Big Pharma. Both companies’ stocks were down less than 1% on Thursday after reporting earnings before the bell. They are both among the pharmaceutical companies that could see…
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone. Top executives from drugmakers big and small told CNBC that the next phase…
Ray Stevens, chief executive officer of Structure Therapeutics Inc., during a Bloomberg Television interview at the JPMorgan Healthcare Conference in San Francisco, Jan. 12, 2026. Benjamin Fanjoy | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe…
